ProfileGDS5678 / 1456920_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 8% 8% 7% 7% 7% 8% 7% 7% 7% 7% 7% 7% 7% 7% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.195828
GSM967853U87-EV human glioblastoma xenograft - Control 22.171938
GSM967854U87-EV human glioblastoma xenograft - Control 32.173337
GSM967855U87-EV human glioblastoma xenograft - Control 42.119447
GSM967856U87-EV human glioblastoma xenograft - Control 52.124257
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.224318
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.18567
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.148457
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.146117
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.159067
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.152637
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.147357
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.164997
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.160477